Why do proteases mess up with antigen presentation by re-shuffling antigen sequences?
• Non-canonical epitopes have emerged as large part of immunopeptidomes. • Spliced peptides represent 20–30% of the MHC-I immunopeptidome variety. • Peptide splicing by proteasome and other proteases is regulated and efficient. • Peptide splicing efficiency can have implications in defining the immu...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Liepe, Juliane [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018 |
|---|
| Umfang: |
6 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND) - Abbate, Marco T.A. ELSEVIER, 2023, Philadelphia, Pa |
|---|---|
| Übergeordnetes Werk: |
volume:52 ; year:2018 ; pages:81-86 ; extent:6 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.coi.2018.04.016 |
|---|
| Katalog-ID: |
ELV043475086 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV043475086 | ||
| 003 | DE-627 | ||
| 005 | 20230624103815.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180726s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.coi.2018.04.016 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000841.pica |
| 035 | |a (DE-627)ELV043475086 | ||
| 035 | |a (ELSEVIER)S0952-7915(17)30200-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Liepe, Juliane |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Why do proteases mess up with antigen presentation by re-shuffling antigen sequences? |
| 264 | 1 | |c 2018 | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Non-canonical epitopes have emerged as large part of immunopeptidomes. • Spliced peptides represent 20–30% of the MHC-I immunopeptidome variety. • Peptide splicing by proteasome and other proteases is regulated and efficient. • Peptide splicing efficiency can have implications in defining the immunological self. | ||
| 700 | 1 | |a Ovaa, Huib |4 oth | |
| 700 | 1 | |a Mishto, Michele |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Current Science |a Abbate, Marco T.A. ELSEVIER |t Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND) |d 2023 |g Philadelphia, Pa |w (DE-627)ELV009957871 |
| 773 | 1 | 8 | |g volume:52 |g year:2018 |g pages:81-86 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.coi.2018.04.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |j Pharmazie |j Pharmazeutika |q VZ |
| 951 | |a AR | ||
| 952 | |d 52 |j 2018 |h 81-86 |g 6 | ||
| author_variant |
j l jl |
|---|---|
| matchkey_str |
liepejulianeovaahuibmishtomichele:2018----:hdpoessespihniepeettobrsufi |
| hierarchy_sort_str |
2018 |
| bklnumber |
44.40 |
| publishDate |
2018 |
| allfields |
10.1016/j.coi.2018.04.016 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000841.pica (DE-627)ELV043475086 (ELSEVIER)S0952-7915(17)30200-5 DE-627 ger DE-627 rakwb eng 610 VZ 15,3 ssgn PHARM DE-84 fid 44.40 bkl Liepe, Juliane verfasserin aut Why do proteases mess up with antigen presentation by re-shuffling antigen sequences? 2018 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Non-canonical epitopes have emerged as large part of immunopeptidomes. • Spliced peptides represent 20–30% of the MHC-I immunopeptidome variety. • Peptide splicing by proteasome and other proteases is regulated and efficient. • Peptide splicing efficiency can have implications in defining the immunological self. Ovaa, Huib oth Mishto, Michele oth Enthalten in Current Science Abbate, Marco T.A. ELSEVIER Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND) 2023 Philadelphia, Pa (DE-627)ELV009957871 volume:52 year:2018 pages:81-86 extent:6 https://doi.org/10.1016/j.coi.2018.04.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.40 Pharmazie Pharmazeutika VZ AR 52 2018 81-86 6 |
| spelling |
10.1016/j.coi.2018.04.016 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000841.pica (DE-627)ELV043475086 (ELSEVIER)S0952-7915(17)30200-5 DE-627 ger DE-627 rakwb eng 610 VZ 15,3 ssgn PHARM DE-84 fid 44.40 bkl Liepe, Juliane verfasserin aut Why do proteases mess up with antigen presentation by re-shuffling antigen sequences? 2018 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Non-canonical epitopes have emerged as large part of immunopeptidomes. • Spliced peptides represent 20–30% of the MHC-I immunopeptidome variety. • Peptide splicing by proteasome and other proteases is regulated and efficient. • Peptide splicing efficiency can have implications in defining the immunological self. Ovaa, Huib oth Mishto, Michele oth Enthalten in Current Science Abbate, Marco T.A. ELSEVIER Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND) 2023 Philadelphia, Pa (DE-627)ELV009957871 volume:52 year:2018 pages:81-86 extent:6 https://doi.org/10.1016/j.coi.2018.04.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.40 Pharmazie Pharmazeutika VZ AR 52 2018 81-86 6 |
| allfields_unstemmed |
10.1016/j.coi.2018.04.016 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000841.pica (DE-627)ELV043475086 (ELSEVIER)S0952-7915(17)30200-5 DE-627 ger DE-627 rakwb eng 610 VZ 15,3 ssgn PHARM DE-84 fid 44.40 bkl Liepe, Juliane verfasserin aut Why do proteases mess up with antigen presentation by re-shuffling antigen sequences? 2018 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Non-canonical epitopes have emerged as large part of immunopeptidomes. • Spliced peptides represent 20–30% of the MHC-I immunopeptidome variety. • Peptide splicing by proteasome and other proteases is regulated and efficient. • Peptide splicing efficiency can have implications in defining the immunological self. Ovaa, Huib oth Mishto, Michele oth Enthalten in Current Science Abbate, Marco T.A. ELSEVIER Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND) 2023 Philadelphia, Pa (DE-627)ELV009957871 volume:52 year:2018 pages:81-86 extent:6 https://doi.org/10.1016/j.coi.2018.04.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.40 Pharmazie Pharmazeutika VZ AR 52 2018 81-86 6 |
| allfieldsGer |
10.1016/j.coi.2018.04.016 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000841.pica (DE-627)ELV043475086 (ELSEVIER)S0952-7915(17)30200-5 DE-627 ger DE-627 rakwb eng 610 VZ 15,3 ssgn PHARM DE-84 fid 44.40 bkl Liepe, Juliane verfasserin aut Why do proteases mess up with antigen presentation by re-shuffling antigen sequences? 2018 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Non-canonical epitopes have emerged as large part of immunopeptidomes. • Spliced peptides represent 20–30% of the MHC-I immunopeptidome variety. • Peptide splicing by proteasome and other proteases is regulated and efficient. • Peptide splicing efficiency can have implications in defining the immunological self. Ovaa, Huib oth Mishto, Michele oth Enthalten in Current Science Abbate, Marco T.A. ELSEVIER Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND) 2023 Philadelphia, Pa (DE-627)ELV009957871 volume:52 year:2018 pages:81-86 extent:6 https://doi.org/10.1016/j.coi.2018.04.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.40 Pharmazie Pharmazeutika VZ AR 52 2018 81-86 6 |
| allfieldsSound |
10.1016/j.coi.2018.04.016 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000841.pica (DE-627)ELV043475086 (ELSEVIER)S0952-7915(17)30200-5 DE-627 ger DE-627 rakwb eng 610 VZ 15,3 ssgn PHARM DE-84 fid 44.40 bkl Liepe, Juliane verfasserin aut Why do proteases mess up with antigen presentation by re-shuffling antigen sequences? 2018 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Non-canonical epitopes have emerged as large part of immunopeptidomes. • Spliced peptides represent 20–30% of the MHC-I immunopeptidome variety. • Peptide splicing by proteasome and other proteases is regulated and efficient. • Peptide splicing efficiency can have implications in defining the immunological self. Ovaa, Huib oth Mishto, Michele oth Enthalten in Current Science Abbate, Marco T.A. ELSEVIER Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND) 2023 Philadelphia, Pa (DE-627)ELV009957871 volume:52 year:2018 pages:81-86 extent:6 https://doi.org/10.1016/j.coi.2018.04.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.40 Pharmazie Pharmazeutika VZ AR 52 2018 81-86 6 |
| language |
English |
| source |
Enthalten in Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND) Philadelphia, Pa volume:52 year:2018 pages:81-86 extent:6 |
| sourceStr |
Enthalten in Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND) Philadelphia, Pa volume:52 year:2018 pages:81-86 extent:6 |
| format_phy_str_mv |
Article |
| bklname |
Pharmazie Pharmazeutika |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND) |
| authorswithroles_txt_mv |
Liepe, Juliane @@aut@@ Ovaa, Huib @@oth@@ Mishto, Michele @@oth@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
ELV009957871 |
| dewey-sort |
3610 |
| id |
ELV043475086 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV043475086</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624103815.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.coi.2018.04.016</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000841.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV043475086</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0952-7915(17)30200-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">15,3</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">PHARM</subfield><subfield code="q">DE-84</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Liepe, Juliane</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Why do proteases mess up with antigen presentation by re-shuffling antigen sequences?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Non-canonical epitopes have emerged as large part of immunopeptidomes. • Spliced peptides represent 20–30% of the MHC-I immunopeptidome variety. • Peptide splicing by proteasome and other proteases is regulated and efficient. • Peptide splicing efficiency can have implications in defining the immunological self.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ovaa, Huib</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mishto, Michele</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Current Science</subfield><subfield code="a">Abbate, Marco T.A. ELSEVIER</subfield><subfield code="t">Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND)</subfield><subfield code="d">2023</subfield><subfield code="g">Philadelphia, Pa</subfield><subfield code="w">(DE-627)ELV009957871</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:52</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:81-86</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.coi.2018.04.016</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-PHARM</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="j">Pharmazie</subfield><subfield code="j">Pharmazeutika</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">52</subfield><subfield code="j">2018</subfield><subfield code="h">81-86</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| author |
Liepe, Juliane |
| spellingShingle |
Liepe, Juliane ddc 610 ssgn 15,3 fid PHARM bkl 44.40 Why do proteases mess up with antigen presentation by re-shuffling antigen sequences? |
| authorStr |
Liepe, Juliane |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV009957871 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 15,3 ssgn PHARM DE-84 fid 44.40 bkl Why do proteases mess up with antigen presentation by re-shuffling antigen sequences? |
| topic |
ddc 610 ssgn 15,3 fid PHARM bkl 44.40 |
| topic_unstemmed |
ddc 610 ssgn 15,3 fid PHARM bkl 44.40 |
| topic_browse |
ddc 610 ssgn 15,3 fid PHARM bkl 44.40 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
h o ho m m mm |
| hierarchy_parent_title |
Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND) |
| hierarchy_parent_id |
ELV009957871 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND) |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV009957871 |
| title |
Why do proteases mess up with antigen presentation by re-shuffling antigen sequences? |
| ctrlnum |
(DE-627)ELV043475086 (ELSEVIER)S0952-7915(17)30200-5 |
| title_full |
Why do proteases mess up with antigen presentation by re-shuffling antigen sequences? |
| author_sort |
Liepe, Juliane |
| journal |
Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND) |
| journalStr |
Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND) |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
81 |
| author_browse |
Liepe, Juliane |
| container_volume |
52 |
| physical |
6 |
| class |
610 VZ 15,3 ssgn PHARM DE-84 fid 44.40 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Liepe, Juliane |
| doi_str_mv |
10.1016/j.coi.2018.04.016 |
| dewey-full |
610 |
| title_sort |
why do proteases mess up with antigen presentation by re-shuffling antigen sequences? |
| title_auth |
Why do proteases mess up with antigen presentation by re-shuffling antigen sequences? |
| abstract |
• Non-canonical epitopes have emerged as large part of immunopeptidomes. • Spliced peptides represent 20–30% of the MHC-I immunopeptidome variety. • Peptide splicing by proteasome and other proteases is regulated and efficient. • Peptide splicing efficiency can have implications in defining the immunological self. |
| abstractGer |
• Non-canonical epitopes have emerged as large part of immunopeptidomes. • Spliced peptides represent 20–30% of the MHC-I immunopeptidome variety. • Peptide splicing by proteasome and other proteases is regulated and efficient. • Peptide splicing efficiency can have implications in defining the immunological self. |
| abstract_unstemmed |
• Non-canonical epitopes have emerged as large part of immunopeptidomes. • Spliced peptides represent 20–30% of the MHC-I immunopeptidome variety. • Peptide splicing by proteasome and other proteases is regulated and efficient. • Peptide splicing efficiency can have implications in defining the immunological self. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA |
| title_short |
Why do proteases mess up with antigen presentation by re-shuffling antigen sequences? |
| url |
https://doi.org/10.1016/j.coi.2018.04.016 |
| remote_bool |
true |
| author2 |
Ovaa, Huib Mishto, Michele |
| author2Str |
Ovaa, Huib Mishto, Michele |
| ppnlink |
ELV009957871 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.coi.2018.04.016 |
| up_date |
2024-07-06T18:55:49.118Z |
| _version_ |
1803857060553555968 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV043475086</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624103815.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.coi.2018.04.016</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000841.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV043475086</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0952-7915(17)30200-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">15,3</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">PHARM</subfield><subfield code="q">DE-84</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Liepe, Juliane</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Why do proteases mess up with antigen presentation by re-shuffling antigen sequences?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Non-canonical epitopes have emerged as large part of immunopeptidomes. • Spliced peptides represent 20–30% of the MHC-I immunopeptidome variety. • Peptide splicing by proteasome and other proteases is regulated and efficient. • Peptide splicing efficiency can have implications in defining the immunological self.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ovaa, Huib</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mishto, Michele</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Current Science</subfield><subfield code="a">Abbate, Marco T.A. ELSEVIER</subfield><subfield code="t">Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND)</subfield><subfield code="d">2023</subfield><subfield code="g">Philadelphia, Pa</subfield><subfield code="w">(DE-627)ELV009957871</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:52</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:81-86</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.coi.2018.04.016</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-PHARM</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="j">Pharmazie</subfield><subfield code="j">Pharmazeutika</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">52</subfield><subfield code="j">2018</subfield><subfield code="h">81-86</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| score |
7.399107 |